No adverse objective or subjective events were noted with the use of the reinfusion drains. No patients had temperature elevations exceeding 38.1°C (100.6°F) in the first 2 days postoperatively ...

Patients receiving an ENaBL therapy need not undergo removal of immune cells for processing and reinfusion, eliminating the complexity and lengthy turnaround time associated with conventional ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

After hours: March 17 at 4:05:09 PM EDT Loading Chart for ANGO ...

Shoreline's approach of developing off-the-shelf (allogeneic) cell therapies – which don't require the convoluted and time-consuming harvesting, modification and reinfusion of patient-derived ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in ...